{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Petrylak DP"],"funding":["NCATS NIH HHS","Bayer HealthCare"],"pagination":["100082"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7985394"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(2)"],"pubmed_abstract":["<h4>Background</h4>In metastatic castration-resistant prostate cancer (mCRPC), assessing treatment response and bone lesions with technetium-99m is limited by image resolution and subjectivity. We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC receiving radium-223 alone or in combination with androgen receptor pathway inhibitors (abiraterone/prednisone or enzalutamide).<h4>Patients and methods</h4>This randomized, non-comparative phase IIa three-arm trial (NCT02034552) evaluated technetium-99m-based BSLA response rate (RR), safety, radiologic progression-free survival (rPFS), and time to first symptomatic skeletal event (SSE) in men with mCRPC and bone metastases receiving radium-223 with/without abiraterone/prednisone or enzalu"],"journal":["ESMO open"],"pubmed_title":["A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide."],"pmcid":["PMC7985394"],"funding_grant_id":["UL1 TR001863"],"pubmed_authors":["Trandafir L","Petrylak DP","Mehlhaff BA","Quinn DI","Dawson NA","Albany C","Siegel J","Vaishampayan UN","Patel KR","Higano CS","Wagner VJ","Nordquist LT","Sartor O"],"additional_accession":[]},"is_claimable":false,"name":"A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.","description":"<h4>Background</h4>In metastatic castration-resistant prostate cancer (mCRPC), assessing treatment response and bone lesions with technetium-99m is limited by image resolution and subjectivity. We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC receiving radium-223 alone or in combination with androgen receptor pathway inhibitors (abiraterone/prednisone or enzalutamide).<h4>Patients and methods</h4>This randomized, non-comparative phase IIa three-arm trial (NCT02034552) evaluated technetium-99m-based BSLA response rate (RR), safety, radiologic progression-free survival (rPFS), and time to first symptomatic skeletal event (SSE) in men with mCRPC and bone metastases receiving radium-223 with/without abiraterone/prednisone or enzalu","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2026-05-02T14:40:14.868Z","creation":"2025-04-03T21:33:42.811Z"},"accession":"S-EPMC7985394","cross_references":{"pubmed":["33744812"],"doi":["10.1016/j.esmoop.2021.100082"]}}